Zydus Lifesciences Limited (ZYDUSLIFE) reports a 29% YoY revenue surge in Q2 FY27, driven by strong performance across its segments.
Zydus Lifesciences Limited (ZYDUSLIFE) partners with Prolific Machines to scale next-gen biologics manufacturing to GMP production.
Zydus Lifesciences Limited (ZYDUSLIFE) receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, gaining 180-day CGT exclusivity.
Zydus Lifesciences Limited (ZYDUSLIFE) signs agreement with Sri Lanka's Board of Investment to build a pharmaceutical manufacturing facility.
Zydus Lifesciences Limited (ZYDUSLIFE) announces the conclusion of USFDA inspection at its Moraiya plant, with 5 observations noted.
Zydus Lifesciences Limited (ZYDUSLIFE) announces USFDA acceptance of FYB206, a biosimilar to Keytruda®.
Zydus Lifesciences Limited (ZYDUSLIFE) unveils new post hoc analysis from Phase 3 EPICS-III trial, showing greater biochemical response with saroglitazar.
Zydus Lifesciences Limited (ZYDUSLIFE) partners with MSN to launch the first generic Adempas® in the U.S.
Zydus Lifesciences Limited (ZYDUSLIFE) announces USFDA inspection conclusion at Ahmedabad plant with one observation, no data integrity issues.
Zydus Lifesciences Limited (ZYDUSLIFE) announces USFDA inspection of pharmacovigilance and post marketing system concludes with nil observations.